董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard J. Nigon | 男 | Director | 68 | 11.95万美元 | 未持股 | 2016-03-25 |
| John Erb | 男 | Director | 67 | 19.50万美元 | 未持股 | 2016-03-25 |
| Paul O'Connell | 男 | Director | 63 | 11.35万美元 | 未持股 | 2016-03-25 |
| Howard Root | 男 | Chief Executive Officer and Director | 55 | 129.75万美元 | 未持股 | 2016-03-25 |
| Jorge Saucedo | 男 | Director | 52 | 11.60万美元 | 未持股 | 2016-03-25 |
| Martin Emerson | 男 | Director | 52 | 11.10万美元 | 未持股 | 2016-03-25 |
| Richard Kramp | 男 | Director | 70 | 11.00万美元 | 未持股 | 2016-03-25 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chad Kugler | 男 | Senior Vice President of Research and Development | 53 | 65.93万美元 | 未持股 | 2016-03-25 |
| Brent Binkowski | 男 | Senior Vice President of Operations | 56 | 未披露 | 未持股 | 2016-03-25 |
| Howard Root | 男 | Chief Executive Officer and Director | 55 | 129.75万美元 | 未持股 | 2016-03-25 |
| Charmaine Sutton | 女 | Senior Vice President, Regulatory & Quality Assurance | 65 | 80.06万美元 | 未持股 | 2016-03-25 |
| James Hennen | 男 | Chief Financial Officer and Senior Vice President of Finance | 52 | 64.04万美元 | 未持股 | 2016-03-25 |
| William Rutstein | 男 | Senior Vice President of International Sales | 72 | 49.35万美元 | 未持股 | 2016-03-25 |
| Carrie Powers | 女 | Senior Vice President of Marketing | 50 | 60.55万美元 | 未持股 | 2016-03-25 |
董事简历
中英对照 | 中文 | 英文- Richard J. Nigon
-
Richard J. Nigon，自2010年2月起担任NTIC董事，自2012年11月起担任该公司非执行主席。Nigon先生是Cedar Point Capital，Inc.的高级副总裁，该公司是一家为早期企业筹集资金的私营公司。从2001年2月到2007年5月，Nigon先生担任私人控股投资公司Miller Johnson Steichen Kinnard（MJSK）的Equity Corporate Finance董事。2006年12月，MJSK被Stifel Nicolaus收购，Nigon先生是Stifel Nicolaus的私募董事总经理。2000年2月至2001年2月，Nigon先生在网络托管公司Dantis，Inc.担任首席财务官。在加入Dantis之前，Nigon先生于1970年至2000年期间受雇于Ernst & Young，LLP，并于1981年至2000年期间担任合伙人。在安永期间，Nigon先生曾担任安永双城创业服务集团的董事，并且是消费零售和制造领域多家上市公司的协调合作伙伴。除NTIC外，Nigon先生还担任Celcuity公司的董事会成员和审计委员会主席，并在多家私营公司的董事会任职。Nigon先生此前曾在Tactile Systems Technology, Inc.、Virtual Radiologic Corporation和微管医疗仪器解决方案公司的董事会任职，直至2017年2月被Teleflex Incorporated收购。
Richard J. Nigon has been a director of NTIC since February 2010 and non executive Chairman of the Board since November 2012. Mr. Nigon is the Senior Vice President of Cedar Point Capital, Inc., a private company that raises capital for early stage companies. From February 2001 until May 2007, Mr. Nigon was a Director of Equity Corporate Finance for Miller Johnson Steichen Kinnard (MJSK), a privately held investment firm. In December 2006, MJSK was acquired by Stifel Nicola, and Mr. Nigon was a Managing Director of Private Placements at Stifel Nicola. From February 2000 to February 2001, Mr. Nigon served as the Chief Financial Officer of Dantis, Inc., a b hosting company. Prior to joining Dantis, Mr. Nigon was employed by Ernst & Young, LLP from 1970 to 2000, where he served as a partner from 1981 to 2000. While at Ernst & Young, Mr. Nigon served as the Director of Ernst & Young's Twin Cities Entrepreneurial Services Group and was the coordinating partner on several publicly traded companies in the consumer retailing and manufacturing sectors. In addition to NTIC, Mr. Nigon also serves on the board of directors of Celcuity Inc. and as chairperson of its audit committee and serves on the board of directors of a number of privately held companies. Mr. Nigon previoly served on the board of directors of Tactile Systems Technology, Inc., Virtual Radiologic Corporation and Vascular Solutions, Inc. until its acquisition by Teleflex Incorporated in February 2017. - Richard J. Nigon，自2010年2月起担任NTIC董事，自2012年11月起担任该公司非执行主席。Nigon先生是Cedar Point Capital，Inc.的高级副总裁，该公司是一家为早期企业筹集资金的私营公司。从2001年2月到2007年5月，Nigon先生担任私人控股投资公司Miller Johnson Steichen Kinnard（MJSK）的Equity Corporate Finance董事。2006年12月，MJSK被Stifel Nicolaus收购，Nigon先生是Stifel Nicolaus的私募董事总经理。2000年2月至2001年2月，Nigon先生在网络托管公司Dantis，Inc.担任首席财务官。在加入Dantis之前，Nigon先生于1970年至2000年期间受雇于Ernst & Young，LLP，并于1981年至2000年期间担任合伙人。在安永期间，Nigon先生曾担任安永双城创业服务集团的董事，并且是消费零售和制造领域多家上市公司的协调合作伙伴。除NTIC外，Nigon先生还担任Celcuity公司的董事会成员和审计委员会主席，并在多家私营公司的董事会任职。Nigon先生此前曾在Tactile Systems Technology, Inc.、Virtual Radiologic Corporation和微管医疗仪器解决方案公司的董事会任职，直至2017年2月被Teleflex Incorporated收购。
- Richard J. Nigon has been a director of NTIC since February 2010 and non executive Chairman of the Board since November 2012. Mr. Nigon is the Senior Vice President of Cedar Point Capital, Inc., a private company that raises capital for early stage companies. From February 2001 until May 2007, Mr. Nigon was a Director of Equity Corporate Finance for Miller Johnson Steichen Kinnard (MJSK), a privately held investment firm. In December 2006, MJSK was acquired by Stifel Nicola, and Mr. Nigon was a Managing Director of Private Placements at Stifel Nicola. From February 2000 to February 2001, Mr. Nigon served as the Chief Financial Officer of Dantis, Inc., a b hosting company. Prior to joining Dantis, Mr. Nigon was employed by Ernst & Young, LLP from 1970 to 2000, where he served as a partner from 1981 to 2000. While at Ernst & Young, Mr. Nigon served as the Director of Ernst & Young's Twin Cities Entrepreneurial Services Group and was the coordinating partner on several publicly traded companies in the consumer retailing and manufacturing sectors. In addition to NTIC, Mr. Nigon also serves on the board of directors of Celcuity Inc. and as chairperson of its audit committee and serves on the board of directors of a number of privately held companies. Mr. Nigon previoly served on the board of directors of Tactile Systems Technology, Inc., Virtual Radiologic Corporation and Vascular Solutions, Inc. until its acquisition by Teleflex Incorporated in February 2017.
- John Erb
-
John Erb先生，自2002年10月是我公司公司董事会成员后，于2011年5担任公司董事会主席。Erb先生在医疗器械行业拥有超过30年的经验。Erb先生自2007年2月起，担任Cardia Access, Inc.公司的首席执行官，这是一家涉及对心脏疾病的治疗及开发新设备的医疗设备公司。2007年间，Erb先生担任CHF Solutions公司董事会执行主席。这是一家参与开发，制造治疗充血性心脏衰竭设备，并且负责分配的一家医疗器械公司。从2001年到2006年公司Erb先生担任CHF Solutions首席执行官。Erb先生从1997年开始在IntraTherapeutics公司担任裁兼首席执行官公司直到2001年该公司被Sulzer Medica 收购。该公司是一家参与末梢血管支架的研发，生产和销售的医疗器械公司。此前，Erb先生是在 Pfizer公司的一个部门--施耐德全球运营任职副总裁。他从2001年10月开始是SenoRx这家上市公司的董事，直到这家公司被C. R. Bard公司于2010年7月收购。同时在2000年10月，他在CryoCath Technologies这家加拿大上市公司任职董事，直到这家公司在2008年12月被收购。Erb先生目前是Sunshine Heart公司、 Osprey医疗公司以及其他几个私人公司的董事。
John Erb has served on our Board since April of 2017. Mr. Erb is currently Chairman of the Board for Nuwellis Inc., a global medical device company involved in the treatment of heart failure, and has been in that role since 2016. He also currently serves as Chairman of the Board of Directors for Osprey Medical, a public ASX company. Mr. Erb is co-founder of NuAx, Inc. formerly Cardia Access, Inc., a medical device company involved in developing new devices for the treatment of heart disease. Previously, Mr. Erb served as Chairman of the Board of Directors for Vascular Solution, Inc., a public NASDAQ company, (acquired by Teleflex Incorporated), and was a board member for CryoCath Technologies (acquired by Medtronic in 2008) and SenoRx, Inc. (acquired by CR Bard in 2010). From 2001 through 2006 Mr. Erb was Chief Executive Officer of CHF Solutions, Inc., a medical device company focused on the treatment of congestive heart failure. CHF Solutions, Inc. was acquired by Gambro. From 1997 through 2001 Mr. Erb was President and Chief Executive Officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral vascular stents. IntraTherapeutics, Inc. was acquired by Sulzer Medica. Other previous executive experience includes Vice President of Operations for Schneider Worldwide, a division of Pfizer, Inc.; ten years with Johnson & Johnson’s Iolab Division; and the start of his career with American Hospital Supply Corporation. Mr. Erb has a B.S. in Business Administration from California State University, Fullerton. - John Erb先生，自2002年10月是我公司公司董事会成员后，于2011年5担任公司董事会主席。Erb先生在医疗器械行业拥有超过30年的经验。Erb先生自2007年2月起，担任Cardia Access, Inc.公司的首席执行官，这是一家涉及对心脏疾病的治疗及开发新设备的医疗设备公司。2007年间，Erb先生担任CHF Solutions公司董事会执行主席。这是一家参与开发，制造治疗充血性心脏衰竭设备，并且负责分配的一家医疗器械公司。从2001年到2006年公司Erb先生担任CHF Solutions首席执行官。Erb先生从1997年开始在IntraTherapeutics公司担任裁兼首席执行官公司直到2001年该公司被Sulzer Medica 收购。该公司是一家参与末梢血管支架的研发，生产和销售的医疗器械公司。此前，Erb先生是在 Pfizer公司的一个部门--施耐德全球运营任职副总裁。他从2001年10月开始是SenoRx这家上市公司的董事，直到这家公司被C. R. Bard公司于2010年7月收购。同时在2000年10月，他在CryoCath Technologies这家加拿大上市公司任职董事，直到这家公司在2008年12月被收购。Erb先生目前是Sunshine Heart公司、 Osprey医疗公司以及其他几个私人公司的董事。
- John Erb has served on our Board since April of 2017. Mr. Erb is currently Chairman of the Board for Nuwellis Inc., a global medical device company involved in the treatment of heart failure, and has been in that role since 2016. He also currently serves as Chairman of the Board of Directors for Osprey Medical, a public ASX company. Mr. Erb is co-founder of NuAx, Inc. formerly Cardia Access, Inc., a medical device company involved in developing new devices for the treatment of heart disease. Previously, Mr. Erb served as Chairman of the Board of Directors for Vascular Solution, Inc., a public NASDAQ company, (acquired by Teleflex Incorporated), and was a board member for CryoCath Technologies (acquired by Medtronic in 2008) and SenoRx, Inc. (acquired by CR Bard in 2010). From 2001 through 2006 Mr. Erb was Chief Executive Officer of CHF Solutions, Inc., a medical device company focused on the treatment of congestive heart failure. CHF Solutions, Inc. was acquired by Gambro. From 1997 through 2001 Mr. Erb was President and Chief Executive Officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral vascular stents. IntraTherapeutics, Inc. was acquired by Sulzer Medica. Other previous executive experience includes Vice President of Operations for Schneider Worldwide, a division of Pfizer, Inc.; ten years with Johnson & Johnson’s Iolab Division; and the start of his career with American Hospital Supply Corporation. Mr. Erb has a B.S. in Business Administration from California State University, Fullerton.
- Paul O'Connell
-
Paul O'Connell自2002年1月起一直担任Vascular Solutions，股份有限公司董事会成员。O'Connell先生曾担任B.Braun Interactive Systems，Inc.的总裁，B.Braun Interactive Systems，Inc.是B.Braun Melsungen AG的全资子公司，是麻醉、强化医学、心脏病学、体外血液治疗和外科以及医院服务的全球供应商，全科医生和家庭护理部门，自2001年起，1989年至2001年，曾任国际医疗器械公司B.Braun Medical的血管介入产品集团副总裁。此外，从1999年到2001年，O'Connell先生为医疗器械公司提供营销和技术支持咨询服务。从1998年到1999年，O'Connell先生是一家医疗器械公司Sablier的所有者，在那里他开发了治疗血栓栓塞性疾病和颈动脉内膜切除术中远端保护的新技术。1993年至1998年，O'Connell先生担任B.Braun Medical的Vena Tech部门的副总裁兼总经理，这是一家他于1988年共同创立的医疗器械公司，并于1993年出售给B.Broun Medical。
Paul O'Connell has served on Vascular Solutions, Inc. Board of Directors since January 2002. Mr. O'Connell has served as President of B. Braun Interventional Systems, Inc., a wholly owned subsidiary of B. Braun Melsungen AG, a global supplier of products for anesthesia, intensive medicine, cardiology, extra corporeal blood treatment and surgery as well as services for hospitals, general practitioners and the homecare sector, since 2001 and was previously Vice President of the Vascular Interventional Products Group of B. Braun Medical, an international medical device company, from 1989 to 2001. In addition, from 1999 through 2001 Mr. O'Connell provided marketing and technical support consulting services to medical device companies. Mr. O'Connell was the owner of Sablier, a medical device company, from 1998 through 1999 where he developed new technologies for the treatment of thromboembolic diseases and for distal protection during carotid endarterectomy. From 1993 through 1998 Mr. O'Connell was Vice President and General Manager of the Vena Tech division of B. Braun Medical, a medical device business he originally co-founded in 1988 and sold to B. Braun Medical in 1993. - Paul O'Connell自2002年1月起一直担任Vascular Solutions，股份有限公司董事会成员。O'Connell先生曾担任B.Braun Interactive Systems，Inc.的总裁，B.Braun Interactive Systems，Inc.是B.Braun Melsungen AG的全资子公司，是麻醉、强化医学、心脏病学、体外血液治疗和外科以及医院服务的全球供应商，全科医生和家庭护理部门，自2001年起，1989年至2001年，曾任国际医疗器械公司B.Braun Medical的血管介入产品集团副总裁。此外，从1999年到2001年，O'Connell先生为医疗器械公司提供营销和技术支持咨询服务。从1998年到1999年，O'Connell先生是一家医疗器械公司Sablier的所有者，在那里他开发了治疗血栓栓塞性疾病和颈动脉内膜切除术中远端保护的新技术。1993年至1998年，O'Connell先生担任B.Braun Medical的Vena Tech部门的副总裁兼总经理，这是一家他于1988年共同创立的医疗器械公司，并于1993年出售给B.Broun Medical。
- Paul O'Connell has served on Vascular Solutions, Inc. Board of Directors since January 2002. Mr. O'Connell has served as President of B. Braun Interventional Systems, Inc., a wholly owned subsidiary of B. Braun Melsungen AG, a global supplier of products for anesthesia, intensive medicine, cardiology, extra corporeal blood treatment and surgery as well as services for hospitals, general practitioners and the homecare sector, since 2001 and was previously Vice President of the Vascular Interventional Products Group of B. Braun Medical, an international medical device company, from 1989 to 2001. In addition, from 1999 through 2001 Mr. O'Connell provided marketing and technical support consulting services to medical device companies. Mr. O'Connell was the owner of Sablier, a medical device company, from 1998 through 1999 where he developed new technologies for the treatment of thromboembolic diseases and for distal protection during carotid endarterectomy. From 1993 through 1998 Mr. O'Connell was Vice President and General Manager of the Vena Tech division of B. Braun Medical, a medical device business he originally co-founded in 1988 and sold to B. Braun Medical in 1993.
- Howard Root
-
Howard Root先生自从在1997年2月共同创立血管解决方案，就担任了本公司首席执行官和公司董事会的一员。1990年至1995年间，Root先生曾受聘于ATS Medical公司，一家机械心脏瓣膜公司。最近担任该公司的副总裁兼总法律顾问。在加盟ATS医疗（ATS Medical）之前，Root先生在Dorsey & Whitney LLP律师事务所从事了五年以上的公司法实行，致力于帮助新兴成长型的代表企业。自1997年共同创办了血管解决方案，成为我们的首席执行官和董事会成员之后，凭借拥有超过20年的医疗器械行业经验，Root先生使得董事会对血管解决方案，及其业务和医疗器械行业有了深入的了解。
Howard Root,has served as our Chief Executive Officer and a member of our Board of Directors since he co-founded Vascular Solutions in February 1997. From 1990 to 1995 Mr. Root was employed by ATS Medical, Inc., a mechanical heart valve company, most recently as Vice President and General Counsel. Prior to joining ATS Medical, Mr. Root practiced corporate law at the law firm of Dorsey & Whitney LLP for over five years, specializing in representing emerging growth companies. - Howard Root先生自从在1997年2月共同创立血管解决方案，就担任了本公司首席执行官和公司董事会的一员。1990年至1995年间，Root先生曾受聘于ATS Medical公司，一家机械心脏瓣膜公司。最近担任该公司的副总裁兼总法律顾问。在加盟ATS医疗（ATS Medical）之前，Root先生在Dorsey & Whitney LLP律师事务所从事了五年以上的公司法实行，致力于帮助新兴成长型的代表企业。自1997年共同创办了血管解决方案，成为我们的首席执行官和董事会成员之后，凭借拥有超过20年的医疗器械行业经验，Root先生使得董事会对血管解决方案，及其业务和医疗器械行业有了深入的了解。
- Howard Root,has served as our Chief Executive Officer and a member of our Board of Directors since he co-founded Vascular Solutions in February 1997. From 1990 to 1995 Mr. Root was employed by ATS Medical, Inc., a mechanical heart valve company, most recently as Vice President and General Counsel. Prior to joining ATS Medical, Mr. Root practiced corporate law at the law firm of Dorsey & Whitney LLP for over five years, specializing in representing emerging growth companies.
- Jorge Saucedo
-
Jorge Saucedo先生自2006年4月始担任公司董事会成员。自2013年6月以来，Saucedo 博士担任NorthShore University HealthSystem心血管研究所的心脏科主任。在此之前，从2002年到2013年期间，Saucedo 博士是俄克拉何马州健康科学中心大学（ University of Oklahoma Health Sciences Center，）的医学教授、副主任、临床事务主任、 心血管科及心导管实验室主任。1998至2002年间，Saucedo 博士的大学是阿肯色大学医学科学（University of Arkansas for Medical Sciences）的内科助理教授，导管实验室主任。Saucedo 博士是研究生的时候，曾获得美国华盛顿特区的华盛顿医院中心（Washington Hospital Center）和密歇根州医院的大学安娜堡分校（the University of Michigan Hospitals, Ann Arbor ）介入性心脏病学的奖学金，以及和 墨西哥的墨西哥城的Instituto Nacional de Cardiologia Cardiologia的“伊格纳西奥·查韦斯，”心脏病学奖学金。
Jorge Saucedo,has served on our Board of Directors since April 2006. Dr. Saucedo is Division Head, Division of Cardiology and Co-Director of the Cardiovascular Institute at NorthShore University HealthSystem, where he has served since June of 2013. Prior to that, Dr. Saucedo was Professor of Medicine, Vice Chief, Clinical Affairs, Cardiovascular Section, and Director, Cardiac Catheterization Laboratories at the University of Oklahoma Health Sciences Center, where he served from 2002 to 2013. Previously, from 1998 to 2002 Dr. Saucedo was Assistant Professor of Internal Medicine, and Director, Catheterization Laboratories at the University of Arkansas for Medical Sciences. Dr. Saucedo’s post-graduate work includes fellowships in interventional cardiology at Washington Hospital Center in Washington, D.C. and the University of Michigan Hospitals, Ann Arbor as well as a cardiology fellowship at Instituto Nacional de Cardiologia “Ignacio Chávez,” Mexico City, Mexico. Dr. Saucedo is board certified in internal medicine, cardiovascular diseases and interventional cardiology. In addition, Dr. Saucedo received a Master of Business Administration degree from University of Arkansas at Little Rock. - Jorge Saucedo先生自2006年4月始担任公司董事会成员。自2013年6月以来，Saucedo 博士担任NorthShore University HealthSystem心血管研究所的心脏科主任。在此之前，从2002年到2013年期间，Saucedo 博士是俄克拉何马州健康科学中心大学（ University of Oklahoma Health Sciences Center，）的医学教授、副主任、临床事务主任、 心血管科及心导管实验室主任。1998至2002年间，Saucedo 博士的大学是阿肯色大学医学科学（University of Arkansas for Medical Sciences）的内科助理教授，导管实验室主任。Saucedo 博士是研究生的时候，曾获得美国华盛顿特区的华盛顿医院中心（Washington Hospital Center）和密歇根州医院的大学安娜堡分校（the University of Michigan Hospitals, Ann Arbor ）介入性心脏病学的奖学金，以及和 墨西哥的墨西哥城的Instituto Nacional de Cardiologia Cardiologia的“伊格纳西奥·查韦斯，”心脏病学奖学金。
- Jorge Saucedo,has served on our Board of Directors since April 2006. Dr. Saucedo is Division Head, Division of Cardiology and Co-Director of the Cardiovascular Institute at NorthShore University HealthSystem, where he has served since June of 2013. Prior to that, Dr. Saucedo was Professor of Medicine, Vice Chief, Clinical Affairs, Cardiovascular Section, and Director, Cardiac Catheterization Laboratories at the University of Oklahoma Health Sciences Center, where he served from 2002 to 2013. Previously, from 1998 to 2002 Dr. Saucedo was Assistant Professor of Internal Medicine, and Director, Catheterization Laboratories at the University of Arkansas for Medical Sciences. Dr. Saucedo’s post-graduate work includes fellowships in interventional cardiology at Washington Hospital Center in Washington, D.C. and the University of Michigan Hospitals, Ann Arbor as well as a cardiology fellowship at Instituto Nacional de Cardiologia “Ignacio Chávez,” Mexico City, Mexico. Dr. Saucedo is board certified in internal medicine, cardiovascular diseases and interventional cardiology. In addition, Dr. Saucedo received a Master of Business Administration degree from University of Arkansas at Little Rock.
- Martin Emerson
-
Martin Emerson先生自2010年5月担任公司董事会。他自2008年4月后一直担任加利尔医疗（Galil Medical）的总裁兼首席执行官，这是一家专注于冷冻疗法的医疗设备公司。2005年至2008年1月，他担任在一家医疗器械公司--美国医疗系统控股公司（American Medical Systems Holdings, Inc.）担任首席执行官。此外在2004年至2005年，他还在该公司担任总裁兼首席运营官。2003年至2004年，担任全球销售和营销的执行副总裁兼首席运营官。2000年至2000年，担任副总裁兼国际部总经理。Emerson先生拥有超过22年的医疗器械行业经验。1998年至2000年间，他在新加坡波士顿科学公司（Boston Scientific Corporation in Singapore ）担任总经理和财务总监。从1997年到1998年，Emerson先生是 新加坡万事达卡国际公司（MasterCard International Incorporated in Singapore ）的副总裁和区域财务总监在1985年至1997年间，他还在百特国际有限公司（Baxter International Inc. ）担任过管理职位。最近担任的职位是其在欧洲医院业务（European Hospital Business ）比利时布鲁塞尔分部时担任的财务副总裁。Emerson先生也是一家上市公司--Wright Medical和一家私人公司--Incisive Surgical的董事之一。
Martin Emerson,has served on our Board of Directors since May 2010. Mr. Emerson has served as President and Chief Executive Officer and director of Galil Medical, a medical device company focused on cryotherapy treatments, since April 2008. He was the President and Chief Executive Officer and a director of American Medical Systems Holdings, Inc., a medical device company, from 2005 to January 2008 where he also served as the President and Chief Operating Officer from 2004 to 2005 the Executive Vice President of Global Sales and Marketing and Chief Operating Officer from 2003 to 2004 and the Vice President and the General Manager of International from 2000 to 2002. Mr. Emerson has over 22 years of experience in the medical device industry. He was the General Manager and Finance Director in Singapore for Boston Scientific Corporation from 1998 to 2000. Mr. Emerson was the Vice President and Regional Financial Officer in Singapore for MasterCard International Incorporated from 1997 to 1998. He also held management positions with Baxter International Inc. from 1985 to 1997 most recently as the Vice President of Finance of its European Hospital Business division in Brussels, Belgium. Mr. Emerson is also a director of Incisive Surgical and Tepha Medical Devices, both private companies, and was a director of Wright Medical, a publicly held medical device company, from April 2006 to October 2015. - Martin Emerson先生自2010年5月担任公司董事会。他自2008年4月后一直担任加利尔医疗（Galil Medical）的总裁兼首席执行官，这是一家专注于冷冻疗法的医疗设备公司。2005年至2008年1月，他担任在一家医疗器械公司--美国医疗系统控股公司（American Medical Systems Holdings, Inc.）担任首席执行官。此外在2004年至2005年，他还在该公司担任总裁兼首席运营官。2003年至2004年，担任全球销售和营销的执行副总裁兼首席运营官。2000年至2000年，担任副总裁兼国际部总经理。Emerson先生拥有超过22年的医疗器械行业经验。1998年至2000年间，他在新加坡波士顿科学公司（Boston Scientific Corporation in Singapore ）担任总经理和财务总监。从1997年到1998年，Emerson先生是 新加坡万事达卡国际公司（MasterCard International Incorporated in Singapore ）的副总裁和区域财务总监在1985年至1997年间，他还在百特国际有限公司（Baxter International Inc. ）担任过管理职位。最近担任的职位是其在欧洲医院业务（European Hospital Business ）比利时布鲁塞尔分部时担任的财务副总裁。Emerson先生也是一家上市公司--Wright Medical和一家私人公司--Incisive Surgical的董事之一。
- Martin Emerson,has served on our Board of Directors since May 2010. Mr. Emerson has served as President and Chief Executive Officer and director of Galil Medical, a medical device company focused on cryotherapy treatments, since April 2008. He was the President and Chief Executive Officer and a director of American Medical Systems Holdings, Inc., a medical device company, from 2005 to January 2008 where he also served as the President and Chief Operating Officer from 2004 to 2005 the Executive Vice President of Global Sales and Marketing and Chief Operating Officer from 2003 to 2004 and the Vice President and the General Manager of International from 2000 to 2002. Mr. Emerson has over 22 years of experience in the medical device industry. He was the General Manager and Finance Director in Singapore for Boston Scientific Corporation from 1998 to 2000. Mr. Emerson was the Vice President and Regional Financial Officer in Singapore for MasterCard International Incorporated from 1997 to 1998. He also held management positions with Baxter International Inc. from 1985 to 1997 most recently as the Vice President of Finance of its European Hospital Business division in Brussels, Belgium. Mr. Emerson is also a director of Incisive Surgical and Tepha Medical Devices, both private companies, and was a director of Wright Medical, a publicly held medical device company, from April 2006 to October 2015.
- Richard Kramp
-
Richard Kramp先生自2013年5月担任公司董事会。Kramp先生从2007年1月至2012年2月曾担任Synovis Life Technologies, Inc.公司的首席执行官和董事，该公司是一提供多种医疗器械的公司。Synovis被百特国际公司（Baxter International, Inc.）收购后，KRAMP先生在2006年6月至2007年1月担任了Synovis公司的总裁。2004年8月至2006年5月，他担任Synovis总裁兼前介入事业部的首席运营官。在加入Synovis，KRAMP先生曾担任一家医疗器械公司Medical CV, Inc.总裁兼首席运营官。而在此之前的1988年至2003年期间，他担任的是该公司新产品开发部的副总裁。1978至1988年期间，Kramp先生先后担任ATS Medical, Inc.公司的总裁兼首席运营官和总裁兼首席执行官以及该公司董事。现在，ATS Medical, Inc.是公司Medtronic, Inc.的一部分。从1981年到1988年kramp先生在圣犹达医疗用品公司（St. Jude Medical, Inc.）从事销售和市场营销，担任销售和营销副总裁。1972年至1978年期间，kramp先生担任Cardiac Pacemakers, Inc. （现为波士顿科学公司 Boston Scientific, Inc.一部分）的设计工程师，电气设计主管。并且还是该公司独立代表公司的区域经理，伊利诺伊州的国家销售经理（Illinois）。目前他担任AUM Cardiovascular， 一家私人，早期的医疗器械公司的董事会成员。并且从2013年1月开始他还是一家上市的医疗器械公司--罗切斯特医学公司（Rochester Medical Corporation）的董事会成员，直到其 被C.R. Bard 于2013年11月收购。
Richard Kramp,has served on our Board of Directors since May 2013. Most recently, Mr. Kramp was the Chief Executive Officer and a director of Synovis Life Technologies, Inc., a diversified medical device company, from January 2007 to February 2012 when Synovis was purchased by Baxter International, Inc. Mr. Kramp served as President of Synovis from June 2006 to January 2007 and from August 2004 to May 2006 he served as President and Chief Operating Officer of the former interventional business unit of Synovis. Prior to joining Synovis, Mr. Kramp served as the Chief Operating Officer of Medical CV, Inc., a medical device company, and before that, as its Vice President of New Product Development. From 1988 to 2003 Mr. Kramp served as President and Chief Operating Officer, and then President, Chief Executive Officer and a director of ATS Medical, Inc. From 1978 to 1988 Mr. Kramp held sales and marketing positions at St. Jude Medical, Inc., serving as Vice President of Sales and Marketing from 1981 to 1988. From 1972 to 1978 Mr. Kramp held the positions of Design Engineer, Supervisor of Electrical Design with Cardiac Pacemakers, Inc. and Territory Manager, then State Sales Manager, with a company serving as an independent representative of Cardiac Pacemakers, Inc. Mr. Kramp currently serves as a director of NVE Corporation, a publicly held technology company, and on the board of AUM Cardiovascular, a private, early stage medical device company. Mr. Kramp served on the board of Rochester Medical Corporation, a publicly held medical device company, from January 2013 until its acquisition by C.R. Bard in November of 2013. - Richard Kramp先生自2013年5月担任公司董事会。Kramp先生从2007年1月至2012年2月曾担任Synovis Life Technologies, Inc.公司的首席执行官和董事，该公司是一提供多种医疗器械的公司。Synovis被百特国际公司（Baxter International, Inc.）收购后，KRAMP先生在2006年6月至2007年1月担任了Synovis公司的总裁。2004年8月至2006年5月，他担任Synovis总裁兼前介入事业部的首席运营官。在加入Synovis，KRAMP先生曾担任一家医疗器械公司Medical CV, Inc.总裁兼首席运营官。而在此之前的1988年至2003年期间，他担任的是该公司新产品开发部的副总裁。1978至1988年期间，Kramp先生先后担任ATS Medical, Inc.公司的总裁兼首席运营官和总裁兼首席执行官以及该公司董事。现在，ATS Medical, Inc.是公司Medtronic, Inc.的一部分。从1981年到1988年kramp先生在圣犹达医疗用品公司（St. Jude Medical, Inc.）从事销售和市场营销，担任销售和营销副总裁。1972年至1978年期间，kramp先生担任Cardiac Pacemakers, Inc. （现为波士顿科学公司 Boston Scientific, Inc.一部分）的设计工程师，电气设计主管。并且还是该公司独立代表公司的区域经理，伊利诺伊州的国家销售经理（Illinois）。目前他担任AUM Cardiovascular， 一家私人，早期的医疗器械公司的董事会成员。并且从2013年1月开始他还是一家上市的医疗器械公司--罗切斯特医学公司（Rochester Medical Corporation）的董事会成员，直到其 被C.R. Bard 于2013年11月收购。
- Richard Kramp,has served on our Board of Directors since May 2013. Most recently, Mr. Kramp was the Chief Executive Officer and a director of Synovis Life Technologies, Inc., a diversified medical device company, from January 2007 to February 2012 when Synovis was purchased by Baxter International, Inc. Mr. Kramp served as President of Synovis from June 2006 to January 2007 and from August 2004 to May 2006 he served as President and Chief Operating Officer of the former interventional business unit of Synovis. Prior to joining Synovis, Mr. Kramp served as the Chief Operating Officer of Medical CV, Inc., a medical device company, and before that, as its Vice President of New Product Development. From 1988 to 2003 Mr. Kramp served as President and Chief Operating Officer, and then President, Chief Executive Officer and a director of ATS Medical, Inc. From 1978 to 1988 Mr. Kramp held sales and marketing positions at St. Jude Medical, Inc., serving as Vice President of Sales and Marketing from 1981 to 1988. From 1972 to 1978 Mr. Kramp held the positions of Design Engineer, Supervisor of Electrical Design with Cardiac Pacemakers, Inc. and Territory Manager, then State Sales Manager, with a company serving as an independent representative of Cardiac Pacemakers, Inc. Mr. Kramp currently serves as a director of NVE Corporation, a publicly held technology company, and on the board of AUM Cardiovascular, a private, early stage medical device company. Mr. Kramp served on the board of Rochester Medical Corporation, a publicly held medical device company, from January 2013 until its acquisition by C.R. Bard in November of 2013.
高管简历
中英对照 | 中文 | 英文- Chad Kugler
Chad Kugler从2014年3月开始担任我司研发部的高级副总裁。加入我司前，从2005年到BridgePoint Medical于2012年被波士顿科技公司（Boston Scientific）收购，他是该公司的联合创始人、总裁和总经理。BridgePoint Medical开发了一套专有的基于导尿管的系统，以治疗冠状慢性完全闭塞病。从2003年到2005年，Kugler先生是Torax Medical的创始团队成员，该公司开发了一种胃酸倒流疾病的治疗方法。从1997年到2001年，Kugler先生担任主动脉血管内移植物公司Teramed的研发部总监，该公司于2001年被Cordis收购。Kugler先生于1992年在SCIMED/Boston Scientific开启其职业生涯。
Chad Kugler has served as our Senior Vice President of Research and Development since March 2014. Prior to joining us, he was the Co-Founder, President and General Manager of BridgePoint Medical, a company that developed a proprietary, catheter-based system to treat coronary chronic total occlusions, from 2005 until its acquisition by Boston Scientific in 2012. From 2003 to 2005 Mr. Kugler was part of the founding team at Torax Medical, which developed a treatment for acid reflux disease. From 1997 to 2001 Mr. Kugler was the Director of Research and Development at Teramed, an aortic endovascular graft company acquired by Cordis in 2001. Mr. Kugler began his career as an engineer with SCIMED/Boston Scientific in 1992.- Chad Kugler从2014年3月开始担任我司研发部的高级副总裁。加入我司前，从2005年到BridgePoint Medical于2012年被波士顿科技公司（Boston Scientific）收购，他是该公司的联合创始人、总裁和总经理。BridgePoint Medical开发了一套专有的基于导尿管的系统，以治疗冠状慢性完全闭塞病。从2003年到2005年，Kugler先生是Torax Medical的创始团队成员，该公司开发了一种胃酸倒流疾病的治疗方法。从1997年到2001年，Kugler先生担任主动脉血管内移植物公司Teramed的研发部总监，该公司于2001年被Cordis收购。Kugler先生于1992年在SCIMED/Boston Scientific开启其职业生涯。
- Chad Kugler has served as our Senior Vice President of Research and Development since March 2014. Prior to joining us, he was the Co-Founder, President and General Manager of BridgePoint Medical, a company that developed a proprietary, catheter-based system to treat coronary chronic total occlusions, from 2005 until its acquisition by Boston Scientific in 2012. From 2003 to 2005 Mr. Kugler was part of the founding team at Torax Medical, which developed a treatment for acid reflux disease. From 1997 to 2001 Mr. Kugler was the Director of Research and Development at Teramed, an aortic endovascular graft company acquired by Cordis in 2001. Mr. Kugler began his career as an engineer with SCIMED/Boston Scientific in 1992.
- Brent Binkowski
Brent Binkowski，他一直是高级运营副总裁（2015年6月以来）。加入之前，他曾担任CeloNova BioSciences公司（一个医疗设备公司，专注于栓塞和血管设备）的运营副总裁（2013年2月至2015年6月）。他曾任职American Medical Systems公司（医疗设备公司，专注于泌尿外科市场）（2003年以来），担任高级运营董事（2011年1月至2013年2月）、价值流董事（从2008年2月到2011年1月）。
Brent Binkowski has served as Senior Vice President of Operations since June 2015. Prior to joining, Mr. Binkowski served as Vice President of Operations for CeloNova BioSciences, Inc., a medical device company focused on embolization and vascular devices, from February 2013 to June 2015. Mr. Binkowski was employed by American Medical Systems, a medical device company focused principally on the urology market, since 2003 serving as Senior Director of Operations from January 2011 to February 2013 and Value Stream Director from February 2008 to January 2011.- Brent Binkowski，他一直是高级运营副总裁（2015年6月以来）。加入之前，他曾担任CeloNova BioSciences公司（一个医疗设备公司，专注于栓塞和血管设备）的运营副总裁（2013年2月至2015年6月）。他曾任职American Medical Systems公司（医疗设备公司，专注于泌尿外科市场）（2003年以来），担任高级运营董事（2011年1月至2013年2月）、价值流董事（从2008年2月到2011年1月）。
- Brent Binkowski has served as Senior Vice President of Operations since June 2015. Prior to joining, Mr. Binkowski served as Vice President of Operations for CeloNova BioSciences, Inc., a medical device company focused on embolization and vascular devices, from February 2013 to June 2015. Mr. Binkowski was employed by American Medical Systems, a medical device company focused principally on the urology market, since 2003 serving as Senior Director of Operations from January 2011 to February 2013 and Value Stream Director from February 2008 to January 2011.
- Howard Root
Howard Root先生自从在1997年2月共同创立血管解决方案，就担任了本公司首席执行官和公司董事会的一员。1990年至1995年间，Root先生曾受聘于ATS Medical公司，一家机械心脏瓣膜公司。最近担任该公司的副总裁兼总法律顾问。在加盟ATS医疗（ATS Medical）之前，Root先生在Dorsey & Whitney LLP律师事务所从事了五年以上的公司法实行，致力于帮助新兴成长型的代表企业。自1997年共同创办了血管解决方案，成为我们的首席执行官和董事会成员之后，凭借拥有超过20年的医疗器械行业经验，Root先生使得董事会对血管解决方案，及其业务和医疗器械行业有了深入的了解。
Howard Root,has served as our Chief Executive Officer and a member of our Board of Directors since he co-founded Vascular Solutions in February 1997. From 1990 to 1995 Mr. Root was employed by ATS Medical, Inc., a mechanical heart valve company, most recently as Vice President and General Counsel. Prior to joining ATS Medical, Mr. Root practiced corporate law at the law firm of Dorsey & Whitney LLP for over five years, specializing in representing emerging growth companies.- Howard Root先生自从在1997年2月共同创立血管解决方案，就担任了本公司首席执行官和公司董事会的一员。1990年至1995年间，Root先生曾受聘于ATS Medical公司，一家机械心脏瓣膜公司。最近担任该公司的副总裁兼总法律顾问。在加盟ATS医疗（ATS Medical）之前，Root先生在Dorsey & Whitney LLP律师事务所从事了五年以上的公司法实行，致力于帮助新兴成长型的代表企业。自1997年共同创办了血管解决方案，成为我们的首席执行官和董事会成员之后，凭借拥有超过20年的医疗器械行业经验，Root先生使得董事会对血管解决方案，及其业务和医疗器械行业有了深入的了解。
- Howard Root,has served as our Chief Executive Officer and a member of our Board of Directors since he co-founded Vascular Solutions in February 1997. From 1990 to 1995 Mr. Root was employed by ATS Medical, Inc., a mechanical heart valve company, most recently as Vice President and General Counsel. Prior to joining ATS Medical, Mr. Root practiced corporate law at the law firm of Dorsey & Whitney LLP for over five years, specializing in representing emerging growth companies.
- Charmaine Sutton
Charmaine Sutton 女士自2010年3月起担任公司运营高级副总裁。Sutton女士此前在2007年7月至2010年3月间担任本公司董事会董事。Sutton女士是一位获得二、三类设备和诊断市场授权监管策略的专家，同时也是ISO13485和FDA QSR质量体系的开发，实施，故障排除和改进方面的专家。1991至2011年间，Sutton女士是塔马拉克集团（The Tamarack Group）的首席顾问兼共同创始人。塔马拉克集团是一个提供监管质量体系活动的机构，是协助开发人员和生产商开发生产医疗设备、诊断、制药、生物制剂和产品组合。顾问协助开发人员和医疗设备。在共同创办的塔马拉克集团之前，萨顿女士在一些创业公司举行董事和副总裁级别工程、监督管理、质量和临床位置等项目，并且是在劳伦斯·利弗莫尔国家实验室（Lawrence Livermore National Laboratory）研究激光聚变计划的科学家之一。2006年到2011年间，Sutton女士在圣克劳德州立大学兼职讲师，讲解管理事务和服务的研究生课程。
Charmaine Sutton has served as our Senior Vice President, Regulatory & Quality Assurance since August 2015. Ms. Sutton served as our Senior Vice President of Operations from March 2010 to August 2015. Ms. Sutton previously served on our Board of Directors from July 2007 to March 2010. From 1991 to 2011 Ms. Sutton was principal consultant and co-founder of The Tamarack Group, an association of consultants assisting developers and manufacturers of medical devices, diagnostics, pharmaceuticals, biologics and combination products with regulatory and quality system activities. Prior to co-founding The Tamarack Group, Ms. Sutton held Director and VP level Engineering, Regulatory, Quality and Clinical positions in start-up companies, and was a research scientist in the laser fusion program at Lawrence Livermore National Laboratory. From 2006 to 2011 Ms. Sutton was an adjunct instructor for the Regulatory Affairs and Services graduate program at St. Cloud State University.- Charmaine Sutton 女士自2010年3月起担任公司运营高级副总裁。Sutton女士此前在2007年7月至2010年3月间担任本公司董事会董事。Sutton女士是一位获得二、三类设备和诊断市场授权监管策略的专家，同时也是ISO13485和FDA QSR质量体系的开发，实施，故障排除和改进方面的专家。1991至2011年间，Sutton女士是塔马拉克集团（The Tamarack Group）的首席顾问兼共同创始人。塔马拉克集团是一个提供监管质量体系活动的机构，是协助开发人员和生产商开发生产医疗设备、诊断、制药、生物制剂和产品组合。顾问协助开发人员和医疗设备。在共同创办的塔马拉克集团之前，萨顿女士在一些创业公司举行董事和副总裁级别工程、监督管理、质量和临床位置等项目，并且是在劳伦斯·利弗莫尔国家实验室（Lawrence Livermore National Laboratory）研究激光聚变计划的科学家之一。2006年到2011年间，Sutton女士在圣克劳德州立大学兼职讲师，讲解管理事务和服务的研究生课程。
- Charmaine Sutton has served as our Senior Vice President, Regulatory & Quality Assurance since August 2015. Ms. Sutton served as our Senior Vice President of Operations from March 2010 to August 2015. Ms. Sutton previously served on our Board of Directors from July 2007 to March 2010. From 1991 to 2011 Ms. Sutton was principal consultant and co-founder of The Tamarack Group, an association of consultants assisting developers and manufacturers of medical devices, diagnostics, pharmaceuticals, biologics and combination products with regulatory and quality system activities. Prior to co-founding The Tamarack Group, Ms. Sutton held Director and VP level Engineering, Regulatory, Quality and Clinical positions in start-up companies, and was a research scientist in the laser fusion program at Lawrence Livermore National Laboratory. From 2006 to 2011 Ms. Sutton was an adjunct instructor for the Regulatory Affairs and Services graduate program at St. Cloud State University.
- James Hennen
James Hennen先生自2004年1月开始担任我公司首席财务总监。从2002年2月到2003年12月担任公司财务总监。再加入我公司之前，Hennen先生曾从事多个会计岗位，最近一次是在一个全球联网的媒体传输信息技术公司WAM!NET, Inc.担任国际财务总监。1997年12月至2002年2月1间，他任职于该公司。1995年10月至1997年10月，Hennen先生是Ernst & Young, LLP的一名核数师。Hennen先生是一名待用的注册会计师。
James Hennen has served as our Chief Financial Officer since January 2004. Mr. Hennen served as our Controller & Director of Finance from February 2002 through December 2003. Prior to joining us, Mr. Hennen served in various accounting positions, most recently as International Controller with WAM!NET, Inc., a globally networked information technology company for media transfer, where he worked from December 1997 through February 2002. From October 1995 through December 1997 Mr. Hennen was an auditor for Ernst & Young, LLP. Mr. Hennen is a Certified Public Accountant inactive.- James Hennen先生自2004年1月开始担任我公司首席财务总监。从2002年2月到2003年12月担任公司财务总监。再加入我公司之前，Hennen先生曾从事多个会计岗位，最近一次是在一个全球联网的媒体传输信息技术公司WAM!NET, Inc.担任国际财务总监。1997年12月至2002年2月1间，他任职于该公司。1995年10月至1997年10月，Hennen先生是Ernst & Young, LLP的一名核数师。Hennen先生是一名待用的注册会计师。
- James Hennen has served as our Chief Financial Officer since January 2004. Mr. Hennen served as our Controller & Director of Finance from February 2002 through December 2003. Prior to joining us, Mr. Hennen served in various accounting positions, most recently as International Controller with WAM!NET, Inc., a globally networked information technology company for media transfer, where he worked from December 1997 through February 2002. From October 1995 through December 1997 Mr. Hennen was an auditor for Ernst & Young, LLP. Mr. Hennen is a Certified Public Accountant inactive.
- William Rutstein
William Rutstein先生自2010年7月担任我公司全球销售高级副总裁。此前，Rutstein先生曾于2008年10月始担任我公司的国际销售副总裁及2008年1月始担任国际销售部高级总监。而他在1999年8月加入Vascular Solutions 后担任了国际销售总监。在加入我们之前的1997年4月至1999年7月期间，Rutstein先生是一家医疗器械公司--Minntech Corporation心脏手术部门的业务部总监。从1988年11月至1997年3月，Rutstein先生就职于一家专门从事心脏病学和电生理导管的医疗器械公司--Daig Corporation a St. Jude Medical Company，他担任改公司区域销售经理、全国销售经理及OEM销售经理和国际销售经理。
William Rutstein has served as our Senior Vice President of International Sales since January 2015. Mr. Rutstein previously served as our Senior Vice President of Worldwide Sales from July 2010 to January 2015 Vice President of International Sales from October 2008 to July 2010 Senior Director of International Sales from January 2008 to October 2008 and Director of International Sales upon joining Vascular Solutions in August 1999 until January 2008. Prior to joining us, Mr. Rutstein was the Business Unit Director for the cardiosurgery division of Minntech Corporation, a medical device company, from April 1997 to July 1999. From November 1988 to March 1997 Mr. Rutstein worked for Daig Corporation a St. Jude Medical Company, a medical device company specializing in cardiology and electrophysiology catheters, where he served as Regional Sales Manager, National Sales Manager, OEM Sales Manager and International Sales Manager.- William Rutstein先生自2010年7月担任我公司全球销售高级副总裁。此前，Rutstein先生曾于2008年10月始担任我公司的国际销售副总裁及2008年1月始担任国际销售部高级总监。而他在1999年8月加入Vascular Solutions 后担任了国际销售总监。在加入我们之前的1997年4月至1999年7月期间，Rutstein先生是一家医疗器械公司--Minntech Corporation心脏手术部门的业务部总监。从1988年11月至1997年3月，Rutstein先生就职于一家专门从事心脏病学和电生理导管的医疗器械公司--Daig Corporation a St. Jude Medical Company，他担任改公司区域销售经理、全国销售经理及OEM销售经理和国际销售经理。
- William Rutstein has served as our Senior Vice President of International Sales since January 2015. Mr. Rutstein previously served as our Senior Vice President of Worldwide Sales from July 2010 to January 2015 Vice President of International Sales from October 2008 to July 2010 Senior Director of International Sales from January 2008 to October 2008 and Director of International Sales upon joining Vascular Solutions in August 1999 until January 2008. Prior to joining us, Mr. Rutstein was the Business Unit Director for the cardiosurgery division of Minntech Corporation, a medical device company, from April 1997 to July 1999. From November 1988 to March 1997 Mr. Rutstein worked for Daig Corporation a St. Jude Medical Company, a medical device company specializing in cardiology and electrophysiology catheters, where he served as Regional Sales Manager, National Sales Manager, OEM Sales Manager and International Sales Manager.
- Carrie Powers
Carrie Powers 女士自2009年7月已成为本公司营销副总裁，2008年6月至2009年6月，Powers女士曾担任产品管理和培训高级经理。2007年3月至2008年7月担任从2008年7月至2009年6月，任职培训总监。从2006年6月至2007年3月，任职Hemostasis Product Line的产品经理。2006年1月至7月间，开始在本公司工作，任职产品经理助理。在加入本公司之前， Powers 女士在2003年至2006年间受雇于威斯康星麦迪逊的玛丽医院（Mary’s Hospital），是该院介入性心导管实验室（Interventional Cardiac Catheterization Lab）的一名注册护士。
Carrie Powers has served as our Senior Vice President of Marketing since January 2016. Ms. Powers previously served as our Vice President of Marketing from July 2009 to December 2015 Senior Director of Product Management and Training from July 2008 to June 2009 Director of Training from March 2007 to July 2008 Product Manager for the Hemostasis Product Line from July 2006 to March 2007 and began her employment with us as an Associate Product Manager for the Hemostasis Product Line from January 2006 to July 2006. Prior to joining us, Ms. Powers was employed by St. Mary’s Hospital in Madison, Wisconsin from 2002 to 2006 most recently as a Registered Nurse in the Interventional Cardiac Catheterization Lab.- Carrie Powers 女士自2009年7月已成为本公司营销副总裁，2008年6月至2009年6月，Powers女士曾担任产品管理和培训高级经理。2007年3月至2008年7月担任从2008年7月至2009年6月，任职培训总监。从2006年6月至2007年3月，任职Hemostasis Product Line的产品经理。2006年1月至7月间，开始在本公司工作，任职产品经理助理。在加入本公司之前， Powers 女士在2003年至2006年间受雇于威斯康星麦迪逊的玛丽医院（Mary’s Hospital），是该院介入性心导管实验室（Interventional Cardiac Catheterization Lab）的一名注册护士。
- Carrie Powers has served as our Senior Vice President of Marketing since January 2016. Ms. Powers previously served as our Vice President of Marketing from July 2009 to December 2015 Senior Director of Product Management and Training from July 2008 to June 2009 Director of Training from March 2007 to July 2008 Product Manager for the Hemostasis Product Line from July 2006 to March 2007 and began her employment with us as an Associate Product Manager for the Hemostasis Product Line from January 2006 to July 2006. Prior to joining us, Ms. Powers was employed by St. Mary’s Hospital in Madison, Wisconsin from 2002 to 2006 most recently as a Registered Nurse in the Interventional Cardiac Catheterization Lab.